


**Listing of Claims:**

Claim 1 (currently amended): A compound of Formula I below:



wherein:

W is selected from the group consisting of hydrogen, monophosphate, diphosphate, and triphosphate; [[,]]

~~W<sup>1</sup> and W<sup>2</sup> are independently selected from the group consisting of hydrogen and a pharmaceutically acceptable prodrug;~~

R is selected from the group consisting of hydrogen or (C<sub>1</sub>-C<sub>3</sub>)alkyl;

R<sup>1</sup> is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl and substituted alkynyl;

Y is a bond, -CH<sub>2</sub>- or -O-;

Y' is selected from the group consisting of hydrogen, halo, hydroxyl, thioalkyl, amino and substituted amino;

Z is selected from the group consisting of formyl, ~~acyl, cyano, carboxyl, carboxyl ester, -C(O)NR<sup>20</sup>R<sup>21</sup>, halo, -B(OH)<sub>2</sub>, -C(=NR<sup>2</sup>)R<sup>3</sup>, nitro, alkenyl, substituted alkenyl, acetylenyl and substituted acetylenyl of the formula -C≡C-R<sup>4</sup>;~~

~~where R<sup>2</sup> is selected from the group consisting of hydrogen, OH, OR<sup>5</sup> amino, substituted amino, and (C<sub>1</sub>-C<sub>2</sub>)alkyl, where R<sup>5</sup> is selected from the group consisting of alkyl and substituted alkyl;~~

~~R<sup>3</sup> is selected from the group consisting of hydrogen, alkyl, substituted alkyl, amino and substituted amino;~~

$R^4$  is selected from the group consisting of hydrogen, phenyl, substituted phenyl, heteroaryl, substituted heteroaryl,  $-\text{Si}(R^8)_3$ , carboxyl, carboxyl esters, and  $-\text{C}(\text{O})\text{NR}^6\text{R}^7$  where  $R^6$  and  $R^7$  are independently hydrogen, alkyl or  $R^6$  and  $R^7$  together with the nitrogen atom pendent thereto are joined to form a heterocyclic, substituted heterocyclic, heteroaryl or substituted heteroaryl group; and

each  $R^8$  is independently  $(\text{C}_1\text{-C}_4)$ alkyl or phenyl; ~~and~~


~~$R^{20}$  and  $R^{21}$  are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic or  $R^{20}$  and  $R^{21}$ , together with the nitrogen atom pendent thereto form a heterocyclic or substituted heterocyclic group;~~

or pharmaceutically acceptable salts thereof.

Claim 2 (currently amended): A compound of claim 1 wherein, W is ~~selected from the group consisting of hydrogen, monophosphate, diphosphate, and triphosphate.~~

Claims 3-4 (canceled).

Claim 5 (currently amended): A compound of Formula II



II

wherein:

W is selected from the group consisting of hydrogen, monophosphate, diphosphate, and triphosphate ~~and a pharmaceutically acceptable prodrug;~~

R is selected from the group consisting of hydrogen or (C<sub>1</sub>-C<sub>3</sub>)alkyl;

Z is selected from the group consisting of formyl, ~~acyl, cyano, carboxyl, carboxyl ester,~~  
~~-C(O)NR<sup>20</sup>R<sup>21</sup>~~; halo, -B(OH)<sub>2</sub>, ~~-C(=NR<sup>2</sup>)R<sup>3</sup>~~; nitro, alkenyl, substituted alkenyl, acetylenyl and  
substituted acetylenyl of the formula -C≡C-R<sup>4</sup>;

~~where R<sup>2</sup> is selected from the group consisting of hydrogen, OH, OR<sup>5</sup> amino,~~  
~~substituted amino, and (C<sub>1</sub>-C<sub>2</sub>)alkyl, where R<sup>5</sup> is selected from the group consisting of alkyl and~~  
~~substituted alkyl;~~

~~R<sup>3</sup> is selected from the group consisting of hydrogen, alkyl, substituted alkyl, amino and~~  
~~substituted amino;~~

R<sup>4</sup> is selected from the group consisting of hydrogen, phenyl, substituted phenyl,  
heteroaryl, substituted heteroaryl, -Si(R<sup>8</sup>)<sub>3</sub>, carboxyl, carboxyl esters, and -C(O)NR<sup>6</sup>R<sup>7</sup> where R<sup>6</sup>  
and R<sup>7</sup> are independently hydrogen, alkyl or R<sup>6</sup> and R<sup>7</sup> together with the nitrogen atom pendent  
thereto are joined to form a heterocyclic, substituted heterocyclic, heteroaryl or substituted  
heteroaryl group; and

each R<sup>8</sup> is independently (C<sub>1</sub>-C<sub>4</sub>)alkyl or phenyl; ~~and~~

~~R<sup>20</sup> and R<sup>21</sup> are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl,~~  
~~heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic or R<sup>20</sup> and R<sup>21</sup>;~~  
~~together with the nitrogen atom pendent thereto form a heterocyclic or substituted heterocyclic~~  
~~group;~~

or pharmaceutically acceptable salts thereof.

Claim 6 (currently amended): A compound of claim 5 wherein, W is ~~selected from the~~  
~~group consisting of hydrogen, monophosphate, diphosphate, and triphosphate.~~

Claim 7 (canceled).

Claim 8 (currently amended): A compound of Claim 7 1 or 5 wherein, Z is selected from formyl, nitro, ~~bromo~~ bromo, iodo, and  $-C\equiv C-R^4$  and  $R^4$  is selected from H, phenyl, and  $-\text{Si}(\text{CH}_3)_3$ .

Claim 9 (currently amended): A compound selected from the group consisting of:

1-(6-hydroxylamino-7-ethynyl-7-deazapurin-9-yl)-2-methyl- $\beta$ -D-ribofuranose (1);

1-(6-hydroxylamino-7-(2-phenylethyn-1-yl)-7-deazapurin-9-yl)-2-methyl- $\beta$ -D-ribofuranose (2);

1-(6-hydroxylamino-7-(2-(pyridin-2-yl)-ethyn-1-yl)-7-deazapurin-9-yl)-2-methyl- $\beta$ -D-ribofuranose (3);

1-(6-hydroxylamino-7-(2-(4-fluorophenyl)ethyn-1-yl)-7-deazapurin-9-yl)-2-methyl- $\beta$ -D-ribofuranose (4);

1-(6-hydroxylamino-7-(2-(4-methylphenyl)ethyn-1-yl)-7-deazapurin-9-yl)-2-methyl- $\beta$ -D-ribofuranose (5);

1-(6-hydroxylamino-7-(2-carboxylethyn-1-yl)-7-deazapurin-9-yl)-2-methyl- $\beta$ -D-ribofuranose (6);

~~1-(6-hydroxylamino-7-(2-ethyl-carboxylethyn-1-yl)-7-deazapurin-9-yl)-2-methyl- $\beta$ -D-ribofuranose (7);~~

1-(6-hydroxylamino-7-(2-ethylcarboxylethyn-1-yl)-7-deazapurin-9-yl)-2-methyl- $\beta$ -D-ribofuranose (7);

1-(6-hydroxylamino-7-(2-carboxamidoethyn-1-yl)-7-deazapurin-9-yl)-2-methyl- $\beta$ -D-ribofuranose (8);

1-(6-hydroxylamino-7-(2-trimethylsilylethyn-1-yl)-7-deazapurin-9-yl)-2-methyl- $\beta$ -D-ribofuranose (9);

1-(6-hydroxylamino-7-ethenyl-7-deazapurin-9-yl)-2-methyl- $\beta$ -D-ribofuranose (10);

1-(6-hydroxylamino-7-formyl-7-deaza-purin-9-yl)-2-methyl-β-D-ribofuranose  
(11);

~~1-(6-hydroxylamino-7-(carbaldehyde-oxime))-7-deazapurin-9-yl)-2-methyl-β-D-ribofuranose (12);~~

~~1-(6-hydroxylamino-7-(boronic acid)-7-deazapurin-9-yl)-2-methyl-β-D-ribofuranose (13);~~

1-(6-hydroxylamino-7-(boronic acid)-7-deazapurin-9-yl)-2-methyl-β-D-ribofuranose (13);

1-(6-hydroxylamino-7-(2,2-difluorovinyl)-7-deazapurin-9-yl)-2-methyl-β-D-ribofuranose (14);

1-(6-hydroxylamino-7-(2-*cis*-methoxyvinyl)-7-deazapurin-9-yl)-2-methyl-β-D-ribofuranose (15);

1-(6-hydroxylamino-7-nitro-7-deaza-purin-9-yl)-2-methyl-β-D-ribofuranose (16);

~~1-(6-hydroxylamino-7-cyano-7-deaza-purin-9-yl)-2-methyl-β-D-ribofuranose (17);~~

1-(6-methoxyamino-7-ethynyl-7-deazapurin-9-yl)-2-methyl-β-D-ribofuranose (18);

1-(6-methoxyamino-7-nitro-7-deaza-purin-9-yl)-2-methyl-β-D-ribofuranose (19);

1-(6-methoxyamino-7-formyl-7-deaza-purin-9-yl)-2-methyl-β-D-ribofuranose (20);

and pharmaceutically acceptable salts thereof.

Claim 10 (original): A pharmaceutical compositions comprising a pharmaceutically acceptable diluent and a therapeutically effective amount of a compound of any one of Claims 1, 5 and 9.

Claims 11-12 (canceled).